JP2021531345A5 - - Google Patents
Info
- Publication number
- JP2021531345A5 JP2021531345A5 JP2021526188A JP2021526188A JP2021531345A5 JP 2021531345 A5 JP2021531345 A5 JP 2021531345A5 JP 2021526188 A JP2021526188 A JP 2021526188A JP 2021526188 A JP2021526188 A JP 2021526188A JP 2021531345 A5 JP2021531345 A5 JP 2021531345A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- antigen
- combination product
- optionally
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18183694 | 2018-07-16 | ||
| EP18183694.1 | 2018-07-16 | ||
| EP19170999.7 | 2019-04-25 | ||
| EP19170999 | 2019-04-25 | ||
| PCT/NL2019/050451 WO2020017962A1 (en) | 2018-07-16 | 2019-07-16 | A combination product for use in tumor vaccination. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021531345A JP2021531345A (ja) | 2021-11-18 |
| JP2021531345A5 true JP2021531345A5 (enExample) | 2022-07-12 |
Family
ID=67544309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021526188A Pending JP2021531345A (ja) | 2018-07-16 | 2019-07-16 | 腫瘍ワクチン接種に用いるための組合せ製品 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11071778B2 (enExample) |
| EP (1) | EP3823668A1 (enExample) |
| JP (1) | JP2021531345A (enExample) |
| CA (1) | CA3104833A1 (enExample) |
| WO (1) | WO2020017962A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110891602A (zh) | 2017-06-23 | 2020-03-17 | 帕多瓦有限责任公司 | 嵌合病毒样颗粒以及其作为免疫反应的抗原特异性重定向剂的用途 |
| CA3104833A1 (en) | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
| JP7641005B2 (ja) | 2018-12-27 | 2025-03-06 | ヴェリミューン インコーポレイテッド | コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用 |
| US11052144B2 (en) | 2019-04-25 | 2021-07-06 | Dcprime B.V. | Methods of tumor vaccination |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| CA3172447A1 (en) * | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2022003568A1 (en) * | 2020-06-30 | 2022-01-06 | Dcprime B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| MX2023004465A (es) | 2020-10-19 | 2023-06-19 | Verimmune Inc | Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer. |
| US20220168407A1 (en) * | 2020-11-05 | 2022-06-02 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
| KR20230135075A (ko) | 2021-01-22 | 2023-09-22 | 멘두스 비.브이. | 종양 백신접종 방법 |
| WO2024197451A1 (en) * | 2023-03-24 | 2024-10-03 | Virogin Biotech (Shanghai) Ltd. | Homologous and heterologous therapeutic vaccination strategies for cancer treatment |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO180167C (no) | 1994-09-08 | 1997-02-26 | Photocure As | Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol |
| US5667786A (en) | 1995-06-07 | 1997-09-16 | Novavax, Inc. | Method for treating tumors with a toxin |
| GB9905911D0 (en) | 1999-03-15 | 1999-05-05 | Photocure As | Method |
| EP1246646A2 (en) | 2000-01-05 | 2002-10-09 | Aventis Pasteur Limited | Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen |
| US7118740B1 (en) * | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
| EP1346059B1 (en) | 2000-11-29 | 2012-05-23 | PCI Biotech AS | Photochemical internalization for delivery of molecules into the cytosol |
| AU2210402A (en) | 2000-11-29 | 2002-06-11 | Norwegian Radium Hospital Res | Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| ES2399386T3 (es) | 2001-04-05 | 2013-04-01 | Novartis Vaccines And Diagnostics, Inc. | Aumento de la inmunidad de las mucosas tras sensibilización parenteral |
| GB0121023D0 (en) | 2001-08-30 | 2001-10-24 | Norwegian Radium Hospital Res | Compound |
| US20040057935A1 (en) | 2002-09-20 | 2004-03-25 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
| JP2006232761A (ja) | 2005-02-25 | 2006-09-07 | Osaka Univ | 制癌剤 |
| WO2006137398A1 (ja) | 2005-06-21 | 2006-12-28 | The Research Foundation For Microbial Diseases Of Osaka University | 癌治療薬 |
| PT2201100E (pt) | 2007-09-14 | 2016-06-03 | Univ Brussel Vrije | Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação |
| US20110110979A1 (en) | 2008-04-16 | 2011-05-12 | Universite De Lausanne | Method and vaccine for optimizing the specific immune responses |
| AU2008285598B2 (en) | 2008-05-19 | 2015-04-16 | Dcprime B.V. | Method for inducing and accelerating cells |
| GB0914286D0 (en) | 2009-08-14 | 2009-09-30 | Pci Biotech As | Method |
| IL224940A (en) | 2010-09-02 | 2017-06-29 | Scripps Research Inst | Providing a drug for growth based on nanoparticles |
| GB201106357D0 (en) * | 2011-04-14 | 2011-06-01 | Pessi Antonello | Composition and uses thereof |
| NL2009102C2 (en) | 2012-07-02 | 2014-01-06 | Dcprime B V | Method for dc-loading. |
| EP2743344A1 (en) | 2012-12-11 | 2014-06-18 | DCPrime B.V. | Therapeutic cancer vaccines derived from a novel dendritic cell line |
| WO2014138314A1 (en) | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| WO2015073801A1 (en) | 2013-11-14 | 2015-05-21 | Duke University | Tetanus toxoid and ccl3 improve dc vaccines |
| GB201519303D0 (en) * | 2015-11-02 | 2015-12-16 | Imp Innovations Ltd | Phagemid vector |
| JP2019526274A (ja) * | 2016-07-21 | 2019-09-19 | ヴァック４オール・ピーティーイー・リミテッドＶａｃ４Ａｌｌ Ｐｔｅ． Ｌｔｄ． | 抗マラリアワクチンとしてのバイオ融合タンパク質 |
| CA3104833A1 (en) | 2018-07-16 | 2020-01-23 | Dcprime B.V. | A combination product for use in tumor vaccination. |
-
2019
- 2019-07-16 CA CA3104833A patent/CA3104833A1/en active Pending
- 2019-07-16 JP JP2021526188A patent/JP2021531345A/ja active Pending
- 2019-07-16 WO PCT/NL2019/050451 patent/WO2020017962A1/en not_active Ceased
- 2019-07-16 EP EP19749853.8A patent/EP3823668A1/en not_active Withdrawn
-
2020
- 2020-04-24 US US16/858,326 patent/US11071778B2/en active Active
-
2021
- 2021-06-29 US US17/361,462 patent/US20220023406A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Nanoparticle‐mediated delivery of inhaled immunotherapeutics for treating lung metastasis | |
| CN112384205B (zh) | 信使rna疫苗及其用途 | |
| Caldeira et al. | Virus-like particles as an immunogenic platform for cancer vaccines | |
| Evtushenko et al. | Plant virus particles with various shapes as potential adjuvants | |
| Rodriguez-Del Rio et al. | A gold glyco-nanoparticle carrying a listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection | |
| Raghuwanshi et al. | Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein | |
| Lin et al. | Programmable macrophage vesicle based bionic self‐adjuvanting vaccine for immunization against monkeypox virus | |
| CA3030451C (en) | Compositions and methods for alphavirus vaccination | |
| Su et al. | Induction of mucosal immunity through systemic immunization: Phantom or reality? | |
| TWI722858B (zh) | 重組李斯特菌疫苗菌株及產製該菌株之方法 | |
| JP2019536464A5 (enExample) | ||
| JP4472724B2 (ja) | パピロマウイルス偽ウイルス及びその調製方法 | |
| Liu et al. | Functional nanomaterials can optimize the efficacy of vaccines | |
| JP2011519869A5 (enExample) | ||
| WO2008019366A3 (en) | Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens | |
| CY1118080T1 (el) | Σωματιδια απελευθερωσης που ομοιαζουν με ιικα σωματιδια για αυτοαντιγραφικα rna μορια | |
| JP2018536002A5 (enExample) | ||
| JP2022530044A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| CN103768595B (zh) | 唑来膦酸佐剂及含唑来膦酸佐剂的疫苗 | |
| JP2015533376A5 (enExample) | ||
| WO2023049636A3 (en) | Cancer therapy compositions and uses thereof | |
| Chakraborty et al. | Ongoing clinical trials of vaccines to fight against COVID-19 pandemic | |
| Cossette et al. | Intranasal subunit vaccination strategies employing nanomaterials and biomaterials | |
| WO2024041612A1 (zh) | 一种正痘病毒属mRNA疫苗及其制备方法和用途 |